Posted by Michael Wonder on 05 Oct 2022
Tecentriq (atezolizumab) receives CADTH reimbursement recommendations for the adjuvant treatment of early-stage non-small-cell lung cancer and the treatment of extensive stage small cell lung cancer
5 October 2022 - The CADTH recommendations are a step towards public funding of this treatment option for some patients with early-stage NSCLC and ES-SCLC.
Roche Canada today announced that the Canadian Agency for Drugs and Technologies in Health (CADTH) pan-Canadian Oncology Drug Review Expert Review Committee (pERC) has issued two final recommendations for Tecentriq (atezolizumab).
